Clinical trials: Systolic Blood Pressure
Hypertension
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80…
- Trial name
- NCT00926289
- Testing
- Telmisartan, Hydrochlorothiazide
- Where
- 106 sites in United States, Bulgaria and 6 more
- Volunteers
- 894 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure
The purpose of this 12-week active controlled trial is to evaluate the safety and efficacy of valsartan 80/160/320 mg (weight stratified) compared with enalapril 10/20/40 mg (weight stratified) on sitting systolic blood pressure…
- Trial name
- NCT00433836
- Testing
- Valsartan, Enalapril
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
- Trial name
- NCT00441064
- Testing
- Aliskiren
- Where
- 19 sites in United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Hypertension
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.
- Trial name
- NCT00819767
- Testing
- Aliskiren, Valsartan
- Where
- 8 sites in Czechia, Hungary and 2 more
- Volunteers
- 68 people
- Sponsor
- Novartis
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Hypertension
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)
More than 80% of older adults have hypertension, with higher prevalence of high systolic blood pressure (SBP) putting them at high risk for cardiovascular (CV) disease and death.
- Trial name
- NCT04112043
- Testing
- Walking Exercise, Nicotinamide Riboside (NR)
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University of Florida
Hypertension, High Blood Pressure
Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
This project will evaluate the clinical and cost effectiveness of a novel, multidisciplinary approach to identify and treat pre-clinical cardiac dysfunction (PCCD) in asymptomatic hypertensive patients identified in a single…
- Conditions
- Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction
- Trial name
- NCT00689819
- Testing
- Exercise, Weight Loss, Low Sodium Diet
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Hypertension, Systolic, Cerebrovascular Disease
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to <130 mmHg (intensive control) versus <145 mmHg (standard control) slows/halts the progression of deterioration of…
- Trial name
- NCT01650402
- Testing
- Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- UConn Health
Hypertension
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.
- Trial name
- NCT00368277
- Testing
- Aliskiren, Ramipril, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 901 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very…
- Trial name
- NCT00698646
- Testing
- Valsartan + HCTZ, Valsartan, HCTZ
- Where
- 20 sites in United States
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Systolic Hypertension
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
- Trial name
- NCT01281306
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 90 sites in United States, Argentina and 7 more
- Volunteers
- 910 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
The purpose of this study is to evaluate the safety and efficacy of three doses of valsartan (0.25, 1.0, and 4.0 mg/kg) on mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) in 6 months…
- Trial name
- NCT00435162
- Testing
- Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Obese Hypertension Study (0954-315)
This is a 16-week study to evaluate high systolic and diastolic blood pressure following treatment in obese, hypertensive, adult patients.
- Trial name
- NCT00289887
- Testing
- Comparator: losartan +/- HCTZ
- Volunteers
- 261 people
- Sponsor
- Organon and Co
Diabetes Mellitus, Type 2
Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes
This study will compare Dulce Digital (i.e., the investigators' proven-effective combination of "one-size-fits-all" educational text messages and nurse monitoring of patient-transmitted blood glucose values) and Dulce Digital-Me…
- Trial name
- DD-Me (NCT03130699)
- Testing
- Dulce Digital, Dulce Digital-Me (Automated Delivery), Dulce Digital-Me (Medical Assistant)
- Where
- 2 sites in United States
- Volunteers
- 310 people
- Sponsor
- Scripps Whittier Diabetes Institute
Hypertension
Nebivolol in Patients With Systolic Stage 2 Hypertension
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
- Trial name
- NEB-MD-20 (NCT01057251)
- Testing
- Nebivolol
- Where
- 36 sites in United States
- Volunteers
- 433 people
- Sponsor
- Forest Laboratories
Chronic Spontaneous Urticaria
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
The purpose of this study was to assess the effect of remibrutinib 25 mg twice a day (b.i.d.) open-label on Systolic Blood Pressure (SBP) measured as a change in 24-hour weighted average SBP from baseline to Week 4 assessed by…
- Trial name
- NCT05795153
- Testing
- LOU064
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.
- Trial name
- NCT02172040
- Testing
- Over-encapsulated 10 mg amlodipine besylate tablet, Over-encapsulated 200 mg celecoxib capsule
- Where
- 10 sites in United Kingdom
- Volunteers
- 152 people
- Sponsor
- Kitov Pharmaceuticals, Ltd.